Why the study?
What is the maximum-tolerable dose of paclitaxel when combined with doxorubicin and dexrazoxane, and does this combination prevent cardiotoxicity in patients with advanced breast cancer?
What is the maximum-tolerable dose of paclitaxel when combined with doxorubicin and dexrazoxane, and does this combination prevent cardiotoxicity in patients with advanced breast cancer?
The combination of paclitaxel, doxorubicin, and dexrazoxane is tolerable at a paclitaxel dose of 150 mg/m2 with G-CSF support, and appears to protect against doxorubicin-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Supports tolerability of paclitaxel 150 mg/m2 with doxorubicin-dexrazoxane; leaves open cardiotoxicity prevention in randomized trials.
Sparano et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: